Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Research] Samsung Electronics (005930) – Mirae Asset Securities | HBM Price · Full-Stack Synergy · Shareholder Return / 2026-08-10 RESEARCH
  • [Disclosure] SK Square (402340) – (Correction) Decision on Paid-in Capital Increase / 2026-07-10 Disclosures
  • [Disclosure] SK Square (402340) – (Correction) Decision on Conclusion of Treasury Stock Trust Agreement / 2024-03-28 Semiconductors
  • [Disclosure] Wonik IPS (240810) – Advance Notice of Financial Results / 2026-04-29 Semiconductors
  • [Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM Demand · AI Accelerator Diversification · Profitability / 2026-01-21 RESEARCH
  • [Disclosure] Hanwha Systems (272210) – Investor Relations (IR) Announcement / 2026-02-06 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Provisional Sales Results (Fair Disclosure) / 2025-05-02 Disclosures
  • [Disclosure] Celltrion (068270) – Decision on Retirement of Shares / 2024-12-04 Disclosures

[Disclosure] Hanwha Aerospace (012450) – Major Management Matters Related to Investment Decision / 2026-03-23

Posted on March 23, 2026August 9, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 Executive Summary

Hanwha Aerospace pre-announced the progress regarding upcoming intra-group contracts with its Polish subsidiary, including a licensing agreement (~KRW 327B) and a parts supply agreement (~KRW 1.9T), to fulfill the 3rd Chunmoo executive contract in Poland.

📊 [Key Disclosure Details & Financial Metrics]

  • Disclosure Title: Major Management Matters Related to Investment Decision — Progress on Upcoming Sales/Supply Contracts with Overseas Subsidiary
  • Background: Execution of planned intra-group contracts to fulfill the 3rd Chunmoo guided missile executive contract (approx. KRW 4.6T excl. VAT) signed in December 2025 with the Polish Armaments Agency via a consortium with subsidiary Hanwha WB Advanced System sp.z o.o.
  • Key Details of Upcoming Contracts:
    • Licensing Agreement:
      • Estimated Contract Amount: Approx. KRW 327.0B
      • Ratio to Recent Revenue (2024 Consolidated Revenue KRW 11.24T): 2.9%
      • Contract Period: Contract Execution Date – October 30, 2033
      • Target Region: Poland
    • Parts Supply Agreement:
      • Estimated Contract Amount: Approx. KRW 1.90T
      • Ratio to Recent Revenue (2024 Consolidated Revenue KRW 11.24T): 16.9%
      • Contract Period: Contract Execution Date – October 30, 2033
      • Target Region: Poland
  • Governance & Approvals: Board approval completed pursuant to Article 542-9 of the Commercial Code; scheduled for reporting at the 49th AGM on March 24, 2026
  • Board Decision / Confirmation Date: March 23, 2026 (Date of decision on contract execution)
  • Notes: FY2025 consolidated revenue (KRW 26.70T per audit report) is subject to approval at the AGM on March 24, 2026. Terms are subject to change, and finalized details will be re-disclosed upon definitive contract execution.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Monitoring the execution of planned follow-up contracts and finalized terms with the overseas subsidiary

This filing serves as a pre-announcement regarding planned licensing and parts supply agreements with a subsidiary to execute the 3rd Polish Chunmoo executive contract. Verifying whether these planned intra-group agreements culminate in executed definitive contracts with finalized terms and financial metrics is essential to determining whether the follow-up contract procedures are completed as planned. Finalized details can be verified in subsequent official DART filings, such as ‘Execution of Sales/Supply Contract’ disclosures, and upcoming periodic financial reports (quarterly, half-yearly, or annual reports).

📢 Disclaimer & Source Notice

Source: This content was structured and newly synthesized based on official data submitted to the Financial Supervisory Service (DART).

Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the individual investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Defense

Post navigation

Previous Post: [Disclosure] Hanwha Systems (272210) – Results of Annual General Meeting of Shareholders / 2026-03-23
Next Post: [Disclosure] ISU PETASYS (007660) – Submission of Audit Report / 2026-03-23

Related Posts

  • [Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-11-21 Disclosures
  • [Disclosure] Samsung Electronics (005930) – (Correction) Provisional Consolidated Financial Performance (Fair Disclosure) / 2024-04-30 Disclosures
  • [Disclosure] ALTEOGEN (196170) – Decision on Bonus Issue / 2026-07-16 Disclosures
  • [Disclosure] Samsung Electronics (005930) – Matters Related to Timely Disclosure Obligations (Fair Disclosure) / 2024-11-15 Semiconductors
  • [Disclosure] Hyundai Motor (005380) – Reference Price for Ex-Interim (Quarterly) Dividend (Hyundai Motor 3rd Preferred B) / 2025-11-26 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Sales and Supply Contract / 2025-09-17 Disclosures
  • [Disclosure] Jeju Semiconductor(080220) – Resolution on Convening of Extraordinary General Meeting of Shareholders / 2026-05-12 Disclosures
  • [Disclosure] Hanwha Systems (272210) – Notice of Corporate Value-up Plan / 2025-05-07 Disclosures
  • [Disclosure] Hana Micron (067310) – Corporate Value-up Plan (Voluntary Disclosure) (2025 Implementation Status) / 2026-05-14 Semiconductors
  • [Disclosure] ALTEOGEN (196170) – Execution of Joint Development and License Agreement for Hyaluronidase / 2024-07-30 Disclosures
  • [Disclosure] LEENO Industrial (058470) – Results of Annual General Meeting of Shareholders / 2024-03-26 Disclosures
  • [Disclosure] Celltrion (068270) – Application for Amendment of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Korea (Correction) / 2026-04-24 Disclosures
  • [Disclosure] KEPCO (015760 / KEP) – Setting of Record Date or Period for Closure of Shareholders’ Register / 2025-04-18 Disclosures
  • [Research] SK hynix (000660 / SKHY) – iM Securities | Legacy DRAM Weakness Risk · HBM Growth Deceleration · Target Price Lowered / 2025-04-25 RESEARCH

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme